Aurinia Pharmaceuticals AUPH Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 89.7%+1.3pp | 88.5%-0.5pp | 88.9%-0.6pp | 89.5%+1.3pp | 88.2%+0.3pp | |
| Operating margin | 41.7%+4.7pp | 37.1%+10.7pp | 26.3%+6.3pp | 20%+7.7pp | 12.3%+14.3pp | |
| Net margin | 100%-1.5pp | 101.5%+72.2pp | 29.3%+6.0pp | 23.3%+7.2pp | 16.1%+13.7pp | |
| EBITDA margin | 48.2%+4.3pp | 43.9%+10.3pp | 33.7%+6.2pp | 27.5%+7.3pp | 20.2%+13.9pp | |
| Returns | ||||||
| Return on equity | 65%+5.1pp | 59.9%+39.3pp | 20.7%+3.3pp | 17.3%+6.1pp | 11.2%+9.7pp | |
| Return on assets | 48.5%+4.4pp | 44.1%+29.7pp | 14.5%+2.6pp | 11.8%+4.0pp | 7.8%+6.8pp | |
| Return on invested capital | 25.2%+3.8pp | 21.4%+4.8pp | 16.7%+3.8pp | 12.8%+5.0pp | 7.9%+9.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.1× | 0.4×-0.1× | 0.5×0.0× | 0.5×0.0× | 0.5×+0.1× | |
| Inventory turnover | 0.7×-0.1× | 0.8×+0.1× | 0.7×+0.1× | 0.6×0.0× | 0.7×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.5×+0.3× | 5.2×-0.5× | 5.8×+0.5× | 5.2×-0.7× | 5.9×+1.4× | |
| Quick ratio | 5×+0.3× | 4.8×-0.4× | 5.2×+0.5× | 4.6×-0.6× | 5.3×+1.1× | |
| Cash ratio | 0.5×-0.4× | 0.9×-0.1× | 1×+0.3× | 0.7×-0.3× | 1×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×-0.1× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Net debt / EBITDA | 0.3×+0.2× | 0.1×-0.1× | 0.2×— | —— | —— | |
| Interest coverage | 29.1×+4.9× | 24.2×+8.4× | 15.8×+4.3× | 11.5×+4.9× | 6.6×+7.6× | |
| Per Share | ||||||
| Book value per share | $4.12-1.6% | $4.19+55.9% | $2.69+10.3% | $2.44-0.3% | $2.45-5.3% | |
| Valuation | ||||||
| Market capitalization | $1.97B-6.3% | $2.1B+44.6% | $1.45B+33.7% | $1.09B-1.5% | $1.1B-14.1% | |
| Enterprise value | $2.01B-4.7% | $2.11B+43.2% | $1.48B+30.3% | $1.13B+0.2% | $1.13B-12.8% | |
| Price / earnings | 6.6×-0.7× | 7.3×-11.4× | 18.7×— | —— | —— | |
| Price / sales | 6.6×-0.8× | 7.4×+2.0× | 5.5×+1.3× | 4.2×-0.3× | 4.5×-1.0× | |
| Price / book | 3.5×-0.1× | 3.6×-0.4× | 4×+0.7× | 3.2×+0.1× | 3.2×-0.3× | |
| EV / EBITDA | 14×-3.0× | 17×+0.5× | 16.5×— | —— | —— | |
| EV / sales | 6.8×-0.7× | 7.5×+1.9× | 5.6×+1.2× | 4.4×-0.2× | 4.6×-0.9× | |
| Earnings yield | 15.1%+1.5pp | 13.7%+8.3pp | 5.4%-0.2pp | 5.6%+2.0pp | 3.6%+3.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aurinia Pharmaceuticals's profit margins?
- Aurinia Pharmaceuticals (AUPH) runs a 89.7% gross margin and a 41.7% operating margin, with a 100.0% net margin.
- Where do Aurinia Pharmaceuticals's ratios come from?
- Every ratio is computed from Aurinia Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.